Ms. Tsuchimoto co-founded Mercaptor Discoveries Inc. and is our part-time Chief Financial Officer. Ms. Tsuchimoto is also the Chief Financial Officer of Monopar Therapeutics since June 2015. Ms. Tsuchimoto has spent over nine years at Raptor Pharmaceuticals, as its Chief Financial Officer from Raptor’s inception in May 2006 until August 2012, as Raptor’s Vice President […]
Annie is the consummate caregiver of the team. She handles finance, benefits, accounting and the wide array of day-to-day operations that make this place run seamlessly. Annie is detail-oriented yet doesn’t sweat the small stuff. She supports the entire Mercaptor team, facilitating our research and helping to build a strong infrastructure and foundation for us […]
Dr. Zankel co-founded and seed-funded Mercaptor Discoveries in 2016. He is also the company’s chief science officer (CSO). Dr. Zankel began his career in drug-development as the fourth employee of BioMarin Pharmaceutical, in 1997, completing his tenure there as Senior Director of Research in 2005. He then co-founded Raptor Pharmaceuticals, in 2006, acting as CSO […]
NOVATO, Calif., Aug. 8, 2017 /PRNewswire/ — Mercaptor Discoveries announces the appointment of three new members to its Board of Directors. Joining the Board of Directors are Erich Sager, Ralph O’Rear and James Kovach, MD, JD. “Our newest Board members embody Mercaptor’s mission of helping millions who suffer from neurodegenerative diseases and brain injury. We […]
https://www.prnewswire.com/news-releases/mercaptor-tackles-neurodegenerative-diseases-300449400.html NOVATO, Calif., May 2, 2017 /PRNewswire/ — Mercaptor Discoveries Inc. (Mercaptor) debuts with a devotion to scientific enquiry, a faith in its singular ability to change the world and experience traveling the roads from bench to clinic. We occupy a niche, early drug-development, largely avoided by “Big Pharma”. The brainchild of industry veterans Sara Isbell […]
